Table 2 ORsa and 95% CIs for the overall association between one s.d. increase in PUFA-specific wPRSs and prostate cancer risk, and associations stratified by potential effect measure modifiers using individual-level data from the PRACTICAL consortium
ω -6 PUFAs | ω -3 PUFAs | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Linoleic acid (LA) | Arachidonic acid (AA) | α -Linolenic acid (ALA) | Eicosapentaenoic acid (EPA) | Docosapentaenoic acid (DPA) | Docosahexaenoic acid (DHA) | ||||||||||||||
Subgroup | Cases/Controls | OR | 95% CI | P -value | OR | 95% CI | P -value | OR | 95% CI | P -value | OR | 95% CI | P -value | OR | 95% CI | P -value | OR | 95% CI | P -value |
Overall | |||||||||||||||||||
All men | 22 721/23 034 | 1.00 | 0.98, 1.02 | 0.65 | 1.01 | 0.99, 1.03 | 0.36 | 0.99 | 0.97, 1.01 | 0.38 | 1.01 | 0.99, 1.03 | 0.31 | 1.01 | 0.99, 1.03 | 0.16 | 1.00 | 0.98, 1.02 | 0.81 |
Smoking status | |||||||||||||||||||
Ever smokers | 4789/4914 | 0.99 | 0.95, 1.04 | 0.81 | 1.01 | 0.97, 1.05 | 0.69 | 0.99 | 0.95, 1.03 | 0.66 | 1.01 | 0.97, 1.06 | 0.65 | 1.01 | 0.97, 1.05 | 0.66 | 1.00 | 0.96, 1.04 | 0.99 |
Never smokers | 3091/2954 | 1.00 | 0.95, 1.06 | 0.98 | 1.01 | 0.95, 1.07 | 0.76 | 0.99 | 0.94, 1.05 | 0.81 | 0.99 | 0.93, 1.04 | 0.62 | 1.00 | 0.94, 1.05 | 0.94 | 0.98 | 0.93, 1.04 | 0.56 |
P interaction b | 0.87 | 0.99 | 0.92 | 0.50 | 0.74 | 0.65 | |||||||||||||
Age | |||||||||||||||||||
<62 years of age | 8259/13 684 | 0.95 | 0.92, 0.98 | 2.6 × 10−4 | 1.05 | 1.02, 1.08 | 2.0 × 10−3 | 0.96 | 0.93, 0.98 | 1.7 × 10−3 | 1.04 | 1.01, 1.06 | 1.7 × 10−2 | 1.05 | 1.02, 1.08 | 2.0 × 10−3 | 1.01 | 0.98, 1.04 | 0.43 |
⩾62 years of age | 14 462/9350 | 1.04 | 1.01, 1.07 | 6.0 × 10−3 | 0.98 | 0.95, 1.01 | 0.11 | 1.02 | 0.99, 1.05 | 0.10 | 0.99 | 0.96, 1.02 | 0.43 | 0.99 | 0.96, 1.01 | 0.28 | 0.99 | 0.96, 1.02 | 0.48 |
P interaction b | 5.2 × 10−6 | 8.5 × 10−4 | 6.5 × 10−4 | 2.3 × 10−2 | 2.8 × 10−3 | 0.29 | |||||||||||||
Disease severity | |||||||||||||||||||
Advanced cancerc | 4802/23 034 | 0.99 | 0.97, 1.01 | 0.24 | 1.01 | 0.99, 1.04 | 0.58 | 0.99 | 0.97, 1.01 | 0.59 | 1.01 | 0.99, 1.03 | 0.96 | 1.02 | 0.99, 1.03 | 0.69 | 1.00 | 0.98, 1.02 | 0.43 |
Non-advanced cancer | 17 919/23 034 | 1.02 | 0.99, 1.05 | 0.31 | 0.99 | 0.96, 1.02 | 0.19 | 1.01 | 0.98, 1.04 | 0.20 | 1.00 | 0.97, 1.03 | 0.23 | 1.01 | 0.97, 1.04 | 0.13 | 1.01 | 0.98, 1.05 | 0.99 |
P homogeneity d | 0.10 | 0.32 | 0.28 | 0.59 | 0.65 | 0.62 | |||||||||||||
Method of detection | |||||||||||||||||||
Screen-detected | 4414/23 034 | 0.98 | 0.94, 1.02 | 0.25 | 1.04 | 0.99, 1.08 | 0.06 | 0.97 | 0.93, 1.00 | 0.07 | 1.03 | 0.99, 1.07 | 0.08 | 1.03 | 0.99, 1.07 | 0.08 | 1.00 | 0.96, 1.04 | 0.93 |
Clinically-detected | 8597/23 034 | 1.00 | 0.97, 1.03 | 0.86 | 1.00 | 0.97, 1.03 | 0.92 | 1.00 | 0.97, 1.03 | 0.98 | 0.99 | 0.96, 1.02 | 0.58 | 1.00 | 0.97, 1.03 | 0.97 | 0.99 | 0.96, 1.02 | 0.52 |
P homogeneity d | 0.43 | 0.15 | 0.20 | 0.12 | 0.24 | 0.69 |